The Medicines Company announced detailed results from ORION-10, the second of three pivotal 18-month low-density lipoprotein cholesterol, or LDL-C, lowering Phase 3 clinical studies of inclisiran, an investigational twice-yearly therapy to reduce LDL-C and the first and only cholesterol-lowering treatment in the siRNA class. In ORION-10, twice-yearly dosing with inclisiran sodium 300 mg met all primary and secondary efficacy endpoints, was well-tolerated and again demonstrated an excellent safety profile. Full study results were presented during a late-breaking science session at the American Heart Association, or AHA, Scientific Sessions in Philadelphia. "Cumulative exposure to high LDL-C levels presents a significant risk of future heart attacks and strokes for millions of people, particularly those with ASCVD," said study principal investigator R. Scott Wright, M.D., Professor of Medicine, Consultant in Cardiology, Mayo Clinic in Rochester, Minnesota. "The data from ORION-10 show that inclisiran lowers LDL-C significantly and sustains reductions over a six-month period with a safety profile similar to placebo."

CN said that the Teamsters Canadian Rail Conference - Conductors, Trainpersons and Yardpersons, or TCRC-CTY, which represents approximately 3,200 CN employees who work as train conductors and railyard coordinators only in Canada, has given the company a 72-hour notice of its intention to strike as of 00:01 hours Eastern Standard Time on November 19. Rob Reilly, executive VP and COO of CN, said: "We continue to negotiate in good faith to reach a fair agreement before the strike deadline. In the spirit of protecting the Canadian economy, we have offered the union binding arbitration and they have declined. If a settlement cannot be reached this weekend, we will once again encourage the union leadership to accept binding arbitration as an alternative to disrupting the Canadian economy. We remain committed to constructive talks to reach an agreement without a work stoppage."

Bristol-Myers Squibb Company (BMY) announced that it currently expects there will be no further extension of the expiration date of the offers to exchange notes issued by Celgene Corporation (CELG) for up to $19.85B aggregate principal amount of new notes to be issued by Bristol-Myers Squibb Company and cash and the related consent solicitations being made by Bristol-Myers Squibb on behalf of Celgene to adopt certain proposed amendments to the indentures governing the Celgene notes. As previously announced, the exchange offers and consent solicitations are currently scheduled to expire on November 20. The closing of the merger is expected to occur on November 20. As a result, Bristol-Myers Squibb currently expects that there will be no further extension of the expiration date as it is anticipated that the merger will be completed on the expiration date. The settlement date for the exchange offers is expected to occur on November 22, 2019.

In an interview on CNBC's Mad Money, Covetrus CEO Ben Wolin said: We have over 100,000 customers in a massive, growing market... We are uniquely positioned... We are making progress in fixing our mistakes... We had far too many initiatives... We need to slow down to speed up... Recent quarterly charges have nothing to do with the potential for this company.

Viacom (VIA) announced continued stays in Scranton, Pennsylvania and Pawnee, Indiana. Under the new pact with NBCUniversal (CMCSA), Comedy Central extended its exclusive cable deal for legendary comedy "The Office" through 2021. After that, the series will continue to air through 2025 in a non-exclusive window on Viacom Media Networks. Additionally, Viacom renewed its cable deal for equally iconic sitcom "Parks and Recreation." All 125 episodes will be able to air on Comedy Central through 2024. "Keeping the exclusive rights to The Office through 2021 is a coup for Comedy Central and Viacom," said Tanya Giles, GM of Comedy Central, Paramount Network, TV Land and Assistant to the Regional Manager of Dunder Mifflin. "Since acquiring it, we've reinvigorated the franchise on linear, drawing big audiences throughout our full day schedule. It's also been a key lead-in to help drive viewers to our own original, acclaimed comedies. We're so excited to keep it on our air that we wouldn't even trade it for an iPod."